Reduction in kidney function decline and risk of severe clinical events in agalsidase beta-treated Fabry disease patients: a matched analysis from the Fabry Registry.
在接受 agalsidase beta 治療的 Fabry 病患者中,腎功能下降及嚴重臨床事件風險的減少:來自 Fabry 註冊的配對分析。
Clin Kidney J 2024-08-14
Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo.
SUSTAIN 6和PIONEER 6試驗的事後分析表明,高心血管風險的2型糖尿病患者接受semaglutide治療,腎功能比安慰劑更穩定。
Kidney Int 2023-08-30
Cluster analysis of kidney function decline among males with Fabry disease in a large United States electronic health records database.
在美國一個龐大的電子健康記錄資料庫中,對患有Fabry病男性進行腎功能衰退的群集分析。
Nephrol Dial Transplant 2023-10-02
Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials.
新型腎臟保護劑對腎臟結局的影響為未來臨床試驗提供了啟示。
Kidney Int 2023-11-22
Dapaglifozin on Albuminuria in Chronic Kidney Disease Patients with FabrY Disease: The DEFY Study Design and Protocol.
Dapagliflozin對Fabry病患者慢性腎臟病合併白蛋白尿的影響:DEFY研究設計與方案。
J Clin Med 2023-06-12
Systems analyses of the Fabry kidney transcriptome and its response to enzyme replacement therapy identified and cross-validated enzyme replacement therapy-resistant targets amenable to drug repurposing.
系統分析法研究法布瑞腎臟轉錄體及其對酶替代治療的反應,識別並交叉驗證對酶替代治療具抗性的標靶,可進行藥物再利用。
Kidney Int 2023-10-02
Impact of kidney biopsy on deciding when to initiate enzyme replacement therapy in children with Fabry disease.
腎臟活檢對於決定何時在兒童中開始進行Fabry病酶替代治療的影響。
Pediatr Nephrol 2023-11-30
A meta-analysis of randomized controlled clinical trials implications of acute treatment effects on glomerular filtration rate for long-term kidney protection.
急性治療對腎小球過濾率長期保護的影響:隨機對照臨床試驗的荟萃分析。
Kidney Int 2024-06-20
Early reduction in albuminuria is associated with a steeper 'dip' in initial estimated glomerular filtration rate but favourable long-term kidney outcomes in people with diabetes receiving sodium-glucose cotransporter-2 inhibitors.
糖尿病患者早期蛋白尿減少與接受鈉葡萄糖共轉運輸蛋白2抑制劑者,初始估計腎小球過濾率下降較快但長期腎臟結果較佳相關。
Diabetes Obes Metab 2024-07-02